Clinical course and prognosis in patients with Gaucher disease and parkinsonism

Neurology: Genetics

Volumn 2, Issue 2, 2016, Pages

  Lopez, Grisel ^a   Kim, Jenny ^a   Wiggs, Edythe ^a   Cintron, Dahima ^a   Groden, Catherine ^a   Tayebi, Nahid ^a   Mistry, Pramod K ^b   Pastores, Gregory M ^c   Zimran, Ari ^d   Goker Alpan, Ozlem ^a,e   Sidransky, Ellen ^a  

^a NATIONAL HUMAN GENOME RESEARCH INSTITUTE   (United States)

^b YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c MATER MISERICORDIAE UNIVERSITY HOSPITAL   (Ireland)

^d HEBREW UNIVERSITY   (Israel)

^e O and O Alpan   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

LEVODOPA;

ACUTE PYELONEPHRITIS; ADOLESCENT; ADULT; ALLELE; ARTICLE; ASPIRATION PNEUMONIA; ASSESSMENT OF HUMANS; AVASCULAR NECROSIS; BLOCK DESIGN; BRIEF VISUOSPATIAL MEMORY TEST REVISED; CHILD; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOMEGALOVIRUS INFECTION; DECUBITUS; DIFFUSE LEWY BODY DISEASE; DIGIT SPAN; DISEASE COURSE; DISEASE DURATION; DISEASE SEVERITY; EPISTAXIS; FEMALE; FOLLOW UP; GAUCHER DISEASE; GENOTYPE; HOPKINS DELAYED MEMORY; HOPKINS IMMEDIATE MEMORY; HUMAN; IMMEDIATE AND DELAYED MEMORY TEST; MALE; MIDDLE AGED; OBSERVATIONAL STUDY; ONSET AGE; OSTEOPOROSIS; PARKINSON DISEASE; PARKINSONISM; PATHOLOGIC FRACTURE; PHENOTYPE; PRESCHOOL CHILD; PRIORITY JOURNAL; PROGNOSIS; RETROSPECTIVE STUDY; SCHOOL CHILD; SMELLING; SPLENOMEGALY; THROMBOCYTOPENIA; UNIFIED PARKINSON DISEASE RATING SCALE; YOUNG ADULT;

EID: 84986892467     PISSN: None     EISSN: 23767839     Source Type: Journal    
DOI: 10.1212/NXG.0000000000000057     Document Type: Article

References (32)

1. McKeran RO, Bradbury P, Taylor D, Stern G. Neurological involvement in type 1 (adult) Gaucher s disease. J Neurol Neurosurg Psychiatry 1985;48:172-175.
2. Neudorfer O, Giladi N, Elstein D, et al. Occurrence of Parkinson s syndrome in type I Gaucher disease. QJM 1996;89:691-694.
3. Machaczka M, Rucinska M, Skotnicki AB, Jurczak W. Parkinson s syndrome preceding clinical manifestation of Gaucher s disease. Am J Hematol 1999;61:216-217.
4. Tayebi N, Callahan M, Madike V, et al. Gaucher disease and parkinsonism: a phenotypic and genotypic characterization. Mol Genet Metab 2001;73:313-321.
5. Itokawa K, Tamura N, Kawai N, Shimazu K, Ishii K. Parkinsonism in type I Gaucher s disease. Intern Med 2006;45:1165-1167.
6. Tayebi N, Walker J, Stubblefield B, et al. Gaucher disease with parkinsonian manifestations: does glucocerebrosidase deficiency contribute to a vulnerability to parkinsonism? Mol Genet Metab 2003;79:104-109.
7. Goker-Alpan O, Schiffmann R, LaMarca ME, Nussbaum RL, McInerney-Leo A, Sidransky E. Parkinsonism among Gaucher disease carriers. J Med Genet 2004;41:937-940.
8. Sidransky E, Nalls MA, Aasly JO, et al. Multicenter analysis of glucocerebrosidase mutations in Parkinson s disease. N Engl J Med 2009;361:1651-1661.
9. Lesage S, Anheim M, Condroyer C, et al. Large-scale screening of the Gaucher s disease-related glucocerebrosidase gene in Europeans with Parkinson s disease. Hum Mol Genet 2011;20:202-210.
10. Nalls MA, Duran R, Lopez G, et al. A multicenter study of glucocerebrosidase mutations in dementia with Lewy bodies. JANALLS M.A.eurol 2013;70:727-735.
11. Mitsui J, Matsukawa T, Sasaki H, et al. Variants associated with Gaucher disease in multiple system atrophy. Ann Clin Transl Neurol 2015;2:417-426.
12. Pringsheim T, Jette N, Frolkis A, Steeves TD. The prevalence of Parkinson s disease: a systematic review and meta-Analysis. Mov Disord 2014;29:1583-1590.
13. Wenger DA, Clark C, Sattler M, Wharton C. Synthetic substrate beta-glucosidase activity in leukocytes: a reproducible method for the identification of patients and carriers of Gaucher s disease. Clin Genet 1978;13: 145-153.
14. Stone DL, Tayebi N, Orvisky E, Stubblefield B, Madike V, Sidransky E. Glucocerebrosidase gene mutations in patients with type 2 Gaucher disease. Hum Mutat 2000;15:181-188.
15. Goker-Alpan O, Lopez G, Vithayathil J, Davis J, Hallett M, Sidransky E. The spectrum of parkinsonian manifestations associated with glucocerebrosidase mutations. Arch Neurol 2008;65:1353-1357.
16. Hughes AJ, Daniel SE, Kilford L, Lees AJ. Accuracy of clinical diagnosis of idiopathic Parkinson s disease: a clinico-pathological study of 100 cases. J Neurol Neurosurg Psychiatry 1992;55:181-184.
17. McKeith IG. Consensus guidelines for the clinical and pathologic diagnosis of dementia with Lewy bodies (DLB): report of the Consortium on DLB International Workshop. J Alzheimers Dis 2006;9(3 suppl): 417-423.
18. Fahn S, Elotion R. UPDRS Program Members. Unified Parkinson s Disease Rating Scale, Vol. 2. Florham Park, NJ: Macmillan Healthcare Information; 1987.
19. Doty RL, Shaman P, Kimmelman CP, Dann MS. University of Pennsylvania Smell Identification Test: a rapid quantitative olfactory function test for the clinic. Laryngoscope 1984;94:176-178.
20. Hughes AJ, Daniel SE, Blankson S, Lees AJ. A clinicopathologic study of 100 cases of Parkinson s disease. Arch Neurol 1993;50:140-148.
21. Mayo MC, Bordelon Y. Dementia with Lewy bodies. Semin Neurol 2014;34:182-188.
22. Molloy S, McKeith IG, O Brien JT, Burn DJ. The role of levodopa in the management of dementia with Lewy bodies. J Neurol Neurosurg Psychiatry 2005;76:1200-1203.
23. Lees AJ, Hardy J, Revesz T. Parkinson s disease. Lancet 2009;373:2055-2066.
24. Goldman JG, Postuma R. Premotor and nonmotor features of Parkinson s disease. Curr Opin Neurol 2014;27: 434-441.
25. Duncan GW, Khoo TK, Yarnall AJ, et al. Health-related quality of life in early Parkinson s disease: the impact of nonmotor symptoms. Mov Disord 2014;29:195-202.
26. Beitz JM. Parkinson s disease: a review. Front Biosci (Schol Ed) 2014;6:65-74.
27. Akbar U, Friedman JH. Recognition and treatment of neuropsychiatric disturbances in Parkinson s disease. Expert Rev Neurother 2015;15:1053-1065.
28. Sato K, Hatano T, Yamashiro K, et al. Prognosis of Parkinson s disease: time to stage III, IV, V, and to motor fluctuations. Mov Disord 2006;21:1384-1395.
29. Kraoua I, Stirnemann J, Ribeiro MJ, et al. Parkinsonism in Gaucher s disease type 1: ten new cases and a review of the literature. Mov Disord 2009;24:1524-1530.
30. Saunders-Pullman R, Hagenah J, Dhawan V, et al. Gaucher disease ascertained through a Parkinson s center: imaging and clinical characterization. Mov Disord 2010; 25:1364-1372.
31. Bultron G, Kacena K, Pearson D, et al. The risk of Parkinson s disease in type 1 Gaucher disease. J Inherit Metab Dis 2010;33:167-173.
32. Rosenbloom B, Balwani M, Bronstein JM, et al. The incidence of Parkinsonism in patients with type 1 Gaucher disease: data from the ICGG Gaucher Registry. Blood Cells Mol Dis 2011;46:95-102.